Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Lindenwood announced in early December that 10 athletic programs, nine varsity sports, would be cut at the end of their respective seasons.For one wrestler, Lindenwood was the perfect fit until the university called a meeting on Dec. 1.
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.